Last reviewed · How we verify
Carbo, 5FU, Cetuximab
Carbo, 5FU, and Cetuximab work together to inhibit DNA synthesis and induce apoptosis in rapidly dividing cancer cells.
Carbo, 5FU, and Cetuximab work together to inhibit DNA synthesis and induce apoptosis in rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Head and neck cancer.
At a glance
| Generic name | Carbo, 5FU, Cetuximab |
|---|---|
| Sponsor | Groupe Oncologie Radiotherapie Tete et Cou |
| Drug class | Antineoplastic agents |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Carbo (capecitabine) is a prodrug that is converted into 5-fluorouracil (5FU), which is a thymidylate synthase inhibitor. 5FU interferes with DNA synthesis, causing cell death in rapidly dividing cancer cells. Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), preventing it from promoting cell proliferation and survival.
Approved indications
- Metastatic colorectal cancer
- Head and neck cancer
Common side effects
- Diarrhea
- Fatigue
- Hand-foot syndrome
- Rash
- Neutropenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carbo, 5FU, Cetuximab CI brief — competitive landscape report
- Carbo, 5FU, Cetuximab updates RSS · CI watch RSS
- Groupe Oncologie Radiotherapie Tete et Cou portfolio CI